Sánchez MLC, Ceballos CNE, Mendoza CE

Language: Spanish
References: 21
Page: 187-192
PDF size: 67.32 Kb.

ABSTRACT

Objective: To know the survival in patients with renal cell carcinoma. Material and methods: Transversal, retrospective, observational, descriptive and open study of the 25 patients with renal cell carcinoma between March 1997 to July 2002. We study the universal variables and we calculate the survival. Results: There were analyzed 25 files of patients with renal cell carcinoma which treatment was only interferon alpha 2. Patients 14 men (54%) and 11 women (44%) with 65 years average. Treatment with interferon was started the next year of diagnostic in 90% of the cases, the other 10% exceeded this time out any treatment. Response was complete in 3 patients (12%) and partial in 7 cases (28%); objective response was observed the four month of started the treatment, three patients survived more than 5 years despite of recurrence with interferon. Survival rate was 54%, 30%, 19%, 15%, 12% to 1, 2, 3, 4, 5 years respectively. Most of patients presented: muscle ache, fever which did not lead to abandon therapy. Conclusions: We do not find significative response. Tumor have high resistance to many forms of treatment, only three patients have a good quality of life (12%) the other patients died for local recurrence (10%) and tumoral activity to distance (90%).

REFERENCES

1. Koening G. Praktische Abhandulungen ueber die Krankheiten der Nier durch Krankheitsfaelle erlaeuter, Leipzing, C Cnobloch, 1826: 307, 21, VII, 8.

2. Waldeyer W. Die entwickelung der carcinome. Arch Pathol Anat Physiol Klin Med 1867; 41: 470-523.

3. Doederlein A. Embryonale Druesengeschwulst der Nierengegend im Kindesalter. Centralbl Krankh Harn Sex Org 1894; 3,88:1 pl.

4. Wingo PA, Tong T. Cancer statistics, 1995. CA Cancer J Clin 1995; 45(1): 8-30.

5. MacDougall ML, Welling LW. Prediction of carcinoma in acquired cystic disease as a function of kidney weight. J Am Soc Nephrol 1990; 1(5): 828-31.

6. Kamel D, Vahakangas K. Proliferating cell nuclear antigen but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma. Histopathology 1994; 25(4): 339-47.

7. Knudsen AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68(4): 820-23.

8. Patel NP, Lavengood RW. Renal cell carcinoma: Natural history and results of treatment. J Urol 1995; 153(3 pt 2): 901-03.

9. Guinan PD, Vozelgan NJ, Fremgen AM et al. Renal cell carcinoma: tumor size, stage and survival. J Urol 1995; 153(3pt2): 901-03.

10. Licht MR, Novick AC. Nephron sparing surgery for renal cell carcinoma. J Urol 1998: 149-1.

11. Isaacs A, Lindemann J. Virus interference. The interferon. Proc R Soc Lond (Biol) 1957; 147: 258-267.

12. Brassard DL, Grace MJ, Bordens RW. Interferon alpha as an immunotherapeutic protein. J Leukoc Biol 2002; 71(4): 565-81.

13. Williams CD, Linch DC. Interferon alpha-2. Br J Hosp Med 1997; 57(9): 436-9.

14. Wadler S. The role of interferons in the treatment of solid tumors. Cancer 1992; 70(4 Suppl): 949-58.

15. Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Seminal Oncol 2002; 29(3 Suppl 7): 18-26.

16. Motzer R, Bander N, Nanus D. Medical progress: Renal-cell carcinoma. N Engl J Med 1996; 335(12); 865-75.

17. Coppin C, Porzsolt F, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000; (3): CD001425.

18. Tian GG, Dawson NA. New agents for treatment of renal cell carcinoma: Expert Rev Anticancer Ther 2001; 1(4): 546-54.

19. Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol 2000; 27(2): 187-93.

20. Mickisch GH, Garin A, Van Poppel H, De Priijck L, Sylvester R. Radical nephrectomy plus interferon alpha based immunotherapy compared with interferon alpha alone in metastatic renal-cell carcinoma: a randomized trial. Lancet 2001; 358(9286): 966-70.

21. Turhal N. Two cases of advanced renal cell cancer with prolonged survival of 8 and 12 years. Lpn J Clin Oncol 2002; 32(4): 152-3.